Related references
Note: Only part of the references are listed.Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic
Chandini M. Thirukkumaran et al.
CANCER RESEARCH (2010)
Intravenous administration of ReolysinA®, a live replication competent RNA virus is safe in patients with advanced solid tumors
Radharani Gollamudi et al.
INVESTIGATIONAL NEW DRUGS (2010)
Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Peter J. Houghton et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
Shizuko Sei et al.
MOLECULAR CANCER (2009)
A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Laura Vidal et al.
CLINICAL CANCER RESEARCH (2008)
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
Jian Qiao et al.
CLINICAL CANCER RESEARCH (2008)
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy
Katie Twigger et al.
CLINICAL CANCER RESEARCH (2008)
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma
F. Errington et al.
GENE THERAPY (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
The pediatric preclinical testing program: Description of models and early testing results
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2007)
Seneca valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers
P. Seshidhar Reddy et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Reovirus oncolysis of human breast cancer
KL Norman et al.
HUMAN GENE THERAPY (2002)
Reovirus as an oncolytic agent against experimental human malignant gliomas
ME Wilcox et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
R Rampling et al.
GENE THERAPY (2000)
Share Paper
